In either eye:

Congenital ptosis.

Presence of either of the following:

1. Pseudo ptosis (upper eyelid dermatochalasis that overhangs the upper eyelid margin); or
2. Dermatochalasis that extends less than 3 mm above the upper eyelid margin.

Neurogenic ptosis (e.g., Horner's syndrome, 3rd cranial nerve palsy).

Myogenic ptosis.

Marcus Gunn jaw-winking syndrome.

Previous ptosis surgery (previous blepharoplasty is allowed provided the surgery took place at least 3 months prior to screening [Visit 1]).

Lid position affected by lid or conjunctival scarring.

Visual field loss from any cause other than ptosis.

History of herpes keratitis.

Poor fixation or abnormal eye position which prevents from taking reliable pictures for MRD1 measurement.

History of closed/narrow angle glaucoma (unless patent peripheral iridotomy has been performed at least 3 months prior to screening (Visit 1).

Facial including periocular neurotoxin (e.g., Botox, Xeomin, Dysport, Myobloc) injections within 3 months prior to screening (Visit 1) and during the study.

Topical application of bimatoprost (i.e., Latisse®) to the eyelashes within 8 days prior to screening (Visit 1) and during the study.

Mechanical ptosis e.g., ptosis due to orbital, corneal or lid tumor, cicatricial processes affecting the movements of the upper lid, and enophthalmos.

Use of topical ophthalmic medications including anti-allergy [e.g., antihistamines], dry eye medications [e.g., IKERVIS®] (except artificial tears with anticipated stable usage during the study), antimicrobial drugs [e.g., antibiotics and antivirals], and anti-inflammatory drugs [including nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids] within 8 days prior to screening (Visit 1) and during the study. Timolol maleate, or sympathetic alpha receptor agonists (e.g., brimonidine tartrate, or apraclonidine hydrochloride) for the treatment of elevated intraocular pressure. Please note that topical ophthalmic prostaglandin analogues for the treatment of elevated intraocular pressure are permitted if dosed in the evening in accordance with the approved prescribing information. All other topical antiglaucoma medications are prohibited.

Any intravitreal injections (e.g., antiVEGFs, steroids) within 8 days prior to screening (Visit

1) and during the study.

Current punctal plugs or placement of punctal plugs during the study.

Current use of OTC vasoconstrictor/decongestant eye medication (e.g., Visine® L.R.®) or any ophthalmic or non-ophthalmic α-adrenergic agonist including OTC products (e.g., Afrin®) at any time during the study, (artificial tears are allowed).

Monoamine oxidase inhibitors (MAOI) (e.g., selegiline hydrochloride, rasagiline mesilate, safinamide mesilate).